)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International (KNSA) investor relations material
Kiniksa Pharmaceuticals International 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary12 Jan, 2026
Key achievements and financial highlights
Reported 2025 unaudited net revenue of $677.5 million, with 62% year-over-year growth and 2026 guidance of $900–$920 million.
Cumulative net revenue for ARCALYST in recurrent pericarditis reached $1.5 billion since launch.
Year-end cash reserves of $414 million support ongoing investment and growth initiatives, with expectations to remain cash flow positive.
ARCALYST market penetration in multiple recurrence patients increased to 18% by end of 2025, up from 13% in 2024.
Over 4,150 prescribers, with 29% prescribing to two or more patients, and 325 new prescribers added in Q4 2025.
Commercial execution and market development
ARCALYST is now positioned as the second-line standard of care after NSAIDs and colchicine, supported by ACC Concise Clinical Guidance.
Innovative AI-driven field alerts and targeted outreach have expanded prescriber base and patient identification.
Growth in pericardial disease centers from 2 at launch to 18, with these centers outpacing other sites in ARCALYST prescriptions.
Real-world evidence from the RESONANCE registry shows ARCALYST adoption is reducing corticosteroid use.
Promotional and medical affairs teams are focused on disseminating new guidelines and data to drive further adoption.
Pipeline and clinical development
KPL-387 is in phase 2/3 dose-finding study for recurrent pericarditis, aiming for commercialization in 2028–2029.
KPL-387 offers monthly dosing via autoinjector, with strong preference from both patients and healthcare professionals.
Phase 2/3 study includes four arms, targeting optimal dose selection for phase 3; topline data expected in second half of 2026.
KPL-1161, an Fc-modified IL-1 alpha and beta inhibitor, is planned to enter the clinic by end of 2026.
Portfolio includes ARCALYST, KPL-387, KPL-1161, and abiprubart, with a focus on cardiovascular and specialty indications.
How to accelerate ARCALYST adoption in first recurrence
How KPL-387 expands recurrent pericarditis market
How continuous ARCALYST therapy redefines patient care
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Kiniksa Pharmaceuticals International earnings date
Q4 202524 Feb, 2026
Kiniksa Pharmaceuticals International
Next Kiniksa Pharmaceuticals International earnings date
Q4 202524 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines. The company's work targets debilitating diseases with significant unmet medical needs, particularly within cardiovascular and autoimmune disorders. Kiniksa's portfolio includes products and candidates based on strong biological rationale or validated mechanisms, offering potential differentiation in treatment approaches. The company is known for its flagship product, ARCALYST, which is used to treat certain inflammatory cardiovascular conditions. The company is headquarted in London, UK, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage